0T6G Stock Overview
A clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Q32 Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.97 |
| 52 Week High | US$53.40 |
| 52 Week Low | US$1.82 |
| Beta | 0 |
| 1 Month Change | -26.48% |
| 3 Month Change | -43.21% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0T6G | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -7.6% | -0.4% | -0.5% |
| 1Y | n/a | -9.4% | 8.5% |
Return vs Industry: Insufficient data to determine how 0T6G performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0T6G performed against the UK Market.
Price Volatility
| 0T6G volatility | |
|---|---|
| 0T6G Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0T6G's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0T6G's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 43 | Jodie Morrison | www.q32bio.com |
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata.
Q32 Bio Inc. Fundamentals Summary
| 0T6G fundamental statistics | |
|---|---|
| Market cap | US$24.40m |
| Earnings (TTM) | -US$47.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 0T6G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0T6G income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$48.14m |
| Gross Profit | -US$48.14m |
| Other Expenses | -US$410.00k |
| Earnings | -US$47.73m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.91 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 223.0% |
How did 0T6G perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 06:09 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Q32 Bio Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Smith | Leerink Partners LLC |
| Jay Olson | Oppenheimer & Co. Inc. |
| Christopher Raymond | Piper Sandler Companies |